Update shared on24 Sep 2025
Fair value Increased 1.80%The slight increase in UCB’s consensus price target to €229.06 reflects improved revenue growth forecasts, while profit margin expectations remain stable.
What's in the News
- Three-year data from BE HEARD trials show sustained efficacy and quality of life improvements with BIMZELX® in moderate-to-severe hidradenitis suppurativa, with better outcomes linked to earlier treatment.
- Long-term open-label extension data for BIMZELX® in moderate-to-severe plaque psoriasis confirm durable complete skin clearance and symptom relief; periodic liver monitoring advised due to reported elevated transaminases.
- "Rheum for Improvement" survey reveals ongoing unmet needs and misconceptions for younger patients with psoriatic arthritis and axial spondyloarthritis, underscoring gaps in education and shared decision-making.
- Phase 3 study of adjunctive fenfluramine in CDKL5 deficiency disorder met primary and key secondary endpoints, with favorable safety profile; product not yet approved for CDD.
- UCB raised 2025 revenue guidance to at least EUR 7 billion and core EPS to at least EUR 7.25.
Valuation Changes
Summary of Valuation Changes for UCB
- The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from €225.00 to €229.06.
- The Consensus Revenue Growth forecasts for UCB has risen from 11.3% per annum to 12.0% per annum.
- The Net Profit Margin for UCB remained effectively unchanged, moving only marginally from 21.74% to 21.33%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.